STERIS plc

STERIS plc

STE

$247.91

Updated: 05/11/2026, 09:23:45

Market Cap
$24.17B
Sector
Healthcare
Industry
Medical - Specialties
Country
US

No historical data available

Company Profile

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.

USD
NYSE
CEO: Daniel A. Carestio
Employees: 17,937
https://www.steris.com
Asset Summaries
Latest generated summaries for STE

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
STE-10-k-fy2026.html2.8 MBtext/htmlENFiled 29/05/2026Period ended 31/03/2026

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2026 filing.

Evidence-backed · 43 KPI observations

Revenue

N/A

FY — · Reported

Net income

$0.8B

FY 2026 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$1.0B

FY 2026 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$0.2B

FY 2026 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Product and service families
Intellectual property portfolio

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

STERIS overview

Leading global infection prevention products and services provider

98%
Source evidence
“STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention.”

Company overview

Global infection prevention products and services provider across healthcare, sterilization, and life sciences

97%
Source evidence
“STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention.”

Reportable segments

Three reportable segments: Healthcare, AST, Life Sciences (Dental divested FY2025)

98%
Source evidence
“We operate and report our financial information in three reportable business segments: Healthcare, AST, and Life Sciences.”

Three reportable segments

Healthcare, AST, Life Sciences; Dental divested fiscal 2025 and reclassified to discontinued operations

98%
Source evidence
“as a result of the fiscal 2025 divestiture of our Dental segment, Dental is presented as discontinued operations.”

Core customer base

Bulk of revenues from healthcare, medical device and pharmaceutical Customers

97%
Source evidence
“The bulk of our revenues are derived from healthcare, medical device and pharmaceutical Customers.”

Product and service families

Consumables, services, capital equipment (sterilizers, surgical tables, AERs), and OR integration connectivity

97%
Source evidence
“consumable products, such as detergents, endoscopy accessories, barrier products, instruments and tools; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, and outsourced reprocessing; capital equipment, such as sterilizers, surgical tables, and automated endoscope reprocessors; and connectivity solutions such as OR integration.”

Intellectual property portfolio

606 US patents, 2,402 foreign patents, 94 US and 235 foreign pending applications, ~2,079 trademarks as of March 31, 2026

96%
Source evidence
“As of March 31, 2026, we held 606 United States patents and 2,402 patents in other jurisdictions”

Revenues by geographic area FY2024-FY2026

FY2026: Ireland $108.5M, United States $4,333.8M, Other locations $1,493.7M

97%
Source evidence
“Ireland$108.5 $107.3 $82.7 United States4,333.8 4,007.6 3,751.4 Other locations1,493.7 1,344.6 1,304.6”

Segment revenues FY2026 vs FY2025 vs FY2024

FY2026: Healthcare $4,208.6M, AST $1,138.5M, Life Sciences $588.8M, Total $5,935.9M

98%
Source evidence
“Revenues$4,208.6 $1,138.5 $588.8 $— $5,935.9”

Revenue by product/service type within segments FY2024-FY2026

FY2026: Healthcare Capital equipment $1,095.9M / Consumables $1,496.6M / Service $1,616.0M; AST Service $1,118.5M; Life Sciences Capital equipment $135.7M / Consumables $308.3M / Service $144.8M

97%
Source evidence
“Healthcare: Capital equipment$1,095.9 $1,037.2 $1,091.5 Consumables1,496.6 1,396.0 1,248.4 Service1,616.0 1,445.4 1,273.1”

Operations and dependencies

Single/limited-source raw materials: ethylene oxide and cobalt-60

Long-term supply contracts for EO and cobalt-60, necessary to AST operations; accelerator-based capacity expansion mitigates cobalt-60 risk

96%
Source evidence
“We have long-term supply contracts for certain materials for which there are few suppliers, or those that are single-sourced in certain regions of the world, such as ethylene oxide ("EO") and radioisotope cobalt-60 ("cobalt-60"), which are necessary to our AST operations.”

Positioning and strategy

Fiscal 2026 tuck-in acquisitions

Two Healthcare tuck-in acquisitions for ~$23.4 million in fiscal 2026

95%
Source evidence
“During fiscal 2026, we completed two tuck-in acquisitions which continued to expand our product and service offerings in the Healthcare segment. Total aggregate consideration was approximately $23.4 million, including fair value of contingent consideration.”

Capital expenditures and FY2027 plans

FY2026 capex $369.0M; FY2027 focus on Healthcare and AST facility expansions and a multi-year service/sales technology project

96%
Source evidence
“In fiscal 2027, we plan to continue to invest in facility expansions, particularly within our Healthcare and AST segments, and in ongoing maintenance for existing facilities. We will also commence a multi-year project to invest in upgraded technology to support our service and sales workflows within our Healthcare and Life Sciences segments.”

Named competitors by segment

Healthcare product competitors include 3M, Baxter, Stryker, Getinge, Olympus; AST competes with Sterigenics; Life Sciences competitors include Belimed, Contec, Ecolab, Fedegari, Getinge, Stilmas

96%
Source evidence
“competitors include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Karl Storz, Olympus, Ruhof, SteelCo, Stryker, Skytron and Wassenburg.”

Aging population and procedure demand

Aging population, rising procedure volumes (endoscopies, colonoscopies), efficiency needs

96%
Source evidence
“increased demand for medical procedures, including preventive screenings such as endoscopies and colonoscopies; and a desire by our Customers to operate more efficiently, all of which are driving increased demand for many of our products and services.”

Demand drivers: aging population and procedure volumes

Growth driven by global population aging and rising medical procedure volumes including endoscopies and colonoscopies

94%
Source evidence
“there is increased demand for medical procedures, including preventive screenings such as endoscopies and colonoscopies; and a desire by our Customers to operate more efficiently, all of which are driving increased demand for many of our products and services.”

Dental segment sale (discontinued operations)

Dental segment sold for $787.5 million cash plus up to $12.5 million contingent; closed May 31, 2024

96%
Source evidence
“On April 11, 2024, the Company announced its plan to sell substantially all of the net assets of its Dental segment for total cash consideration of $787.5 million... The transaction was structured as an equity sale and closed on May 31, 2024.”

AST global network and technology-neutral offering

Global contract sterilization/testing network in Americas, Europe, Asia; service support for global installed base of integrated sterilization equipment

95%
Source evidence
“Our AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems.”

Risks, financing, and outlook

Tariffs and inflation headwinds

Tariffs and inflation offset pricing and productivity gains in gross profit

94%
Source evidence
“Favorable impacts from pricing, operational improvements and lower restructuring costs, and productivity were partially offset by unfavorable impacts from tariffs and inflation.”

Total sources of credit at March 31, 2026

Total credit sources $3,007.8M; Revolver $1,100.0M with $1,052.5M available; Private Placement Notes $557.8M; Senior Public Notes $1,350.0M

98%
Source evidence
“Private Placement Senior Notes$557.8 — $557.8 $— Revolving Credit Facility (1) 1,100.0 9.8 37.8 1,052.5 Senior Public Notes1,350.0 — 1,350.0 — Total Sources of Credit$3,007.8 $9.8 $1,945.6 $1,052.5”

Senior Public Notes tranches

$675.0M 2.700% notes due 2031 and $675.0M 3.750% notes due 2051 issued by FinCo, guaranteed senior unsecured

97%
Source evidence
“(i) $675.0 million aggregate principal amount of the FinCo’s 2.700% Senior Notes due 2031 (the “2031 Notes”) and (ii) $675.0 million aggregate principal amount of the FinCo’s 3.750% Senior Notes due 2051”

Revolving Credit Agreement terms

$1,100.0M revolver maturing October 2029, $625.0M accordion, pricing based on Debt Rating

96%
Source evidence
“entered into a credit agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as administrative agent (the “Revolving Credit Agreement”) providing for a $1,100.0 million revolving credit facility”

Leverage ratio

Debt-to-total capital ratio 21.3% at March 31, 2026 vs 23.6% at March 31, 2025

95%
Source evidence
“Our debt-to-total capital ratio was 21.3% at March 31, 2026 and 23.6% at March 31, 2025.”

Outstanding borrowings at fiscal year end

$37.8M outstanding under revolver at March 31, 2026 vs $34.8M at end of fiscal 2025

93%
Source evidence
“bank credit facility, compared to $34.8 million at the end of fiscal 2025.”

Fiscal 2026 financial highlights

FY2026 revenue $5,935.9M (+8.7%), operating income $1,101.8M (+27.1%), FCF $982.9M, debt/capital 21.3%, dividend $0.63/share

97%
Source evidence
“Revenues increased $476.4 million, or 8.7%, to $5,935.9 million for the year ended March 31, 2026, as compared to $5,459.5 million for the year ended March 31, 2025.”

Funding strategy for capital requirements

Intends to fund capex and liquidity needs with cash and operations; may raise additional debt or equity if needed

93%
Source evidence
“To the extent that existing and anticipated sources of cash are not sufficient to fund our future activities, we may need to raise additional funds through additional borrowings or the sale of equity securities.”

Cash dividends paid

FY2026 dividends $241.8M ($2.46/share) vs FY2025 $219.9M ($2.23/share)

98%
Source evidence
“During fiscal 2026, we paid cash dividends totaling $241.8 million or $2.46 per outstanding share.”

New $1,000.0M share repurchase program

Board terminated Outgoing Repurchase Program and authorized New Repurchase Program of up to $1,000.0M on May 5, 2026

97%
Source evidence
“On May 5, 2026, the Board of Directors terminated the Outgoing Repurchase Program and authorized the New Repurchase Program for the purchase of up to $1,000.0 million”

Share-based compensation repurchases and option proceeds

$12.5M of share-based comp share repurchases and $32.9M option exercise proceeds in FY2026

90%
Source evidence
“we received cash proceeds totaling $32.9 million and $25.5 million, respectively, under these programs”

FDA and international regulatory requirements

Extensive FDA and EEA regulatory approval/clearance requirements for products and services

95%
Source evidence
“Our operations are subject to extensive regulation in the countries where we do business. In the U.S., our products and services are regulated by the FDA and other regulatory authorities.”

FDA/Regulatory compliance status

No FDA enforcement actions, zero MedWatch listings, no Class I recalls in FY2026-FY2024

94%
Source evidence
“In fiscal 2026, STERIS was not the subject of any FDA or Regulatory Authority enforcement actions.”

Tariffs and USMCA review risk

Tariffs and USMCA 2026 joint review could affect manufacturing in Canada and Mexico

93%
Source evidence
“The first such review is expected to commence on July 1, 2026... Changes to the USMCA could adversely affect our manufacturing operations and those of our suppliers in Canada and Mexico.”

Healthcare reimbursement and Medicaid funding risk

Reimbursement pressure and OBBBA Medicaid funding cuts may hurt Customer purchases

93%
Source evidence
“in 2025, the United States passed the One Big Beautiful Bill Act (the "OBBBA") which may reduce Medicaid funding, result in decreased Medicaid reimbursements and negatively impact Customers who purchase our products and services.”

Trade regulation/tariff risk including from Irish corporate structure

Risks from U.S. trade regulation, potential U.S. tax residency treatment, and tariffs/trade barriers tied to STERIS's corporate structure

90%
Source evidence
“changes in tax laws that would result in STERIS being treated as a U.S. resident for U.S. federal tax purposes, or the impact of tariffs and/or other trade barriers as a result of STERIS's corporate structure”

Macro, geopolitical, and cybersecurity risks

International unrest, military conflicts, economic downturns, currency fluctuations, cybersecurity events, inflation, and labor disruptions could affect results

85%
Source evidence
“the potential of international unrest, military conflicts, economic downturns, currency fluctuations and cybersecurity events and any resulting effects on STERIS's anticipated growth, performance or other results”

Healthcare policy and reimbursement risk

Changes in healthcare policy or third-party payor reimbursement levels could affect results

85%
Source evidence
“changes in healthcare policy or government or other third-party payor reimbursement levels”

Debt level and credit access risks

Indebtedness may limit financial flexibility/increase borrowing costs; credit availability changes could affect STERIS, Customers and suppliers

85%
Source evidence
“the level of STERIS's indebtedness limiting financial flexibility or increasing future borrowing costs”

Material exposure graph

Aging population
Demand Driver

Growth in healthcare, medical device, and pharmaceutical customer industries is driven by global population aging, increasing healthcare consumption.

Relevance 88·Dependency 70·Confidence 92
Source evidence
“Much of the growth in these industries is driven by the aging of the population throughout the world”
ethylene oxide (EO)
Supplier Dependency

EO is necessary to AST operations and is single-sourced or limited-supplier in certain regions, secured through long-term supply contracts.

Relevance 85·Dependency 80·Confidence 93
Source evidence
“such as ethylene oxide ("EO") and radioisotope cobalt-60 ("cobalt-60"), which are necessary to our AST operations.”
FDA regulations
Regulatory Exposure

Nearly all aspects of STERIS product testing, manufacturing, labeling and distribution are regulated by FDA; sanctions for non-compliance include recalls, fines and penalties.

Relevance 85·Dependency 75·Confidence 93
Source evidence
“Government regulation applies to nearly all aspects of testing, manufacturing, safety, labeling, storing, recordkeeping, reporting, promoting, distributing, and importing or exporting of medical devices”
Aging population
Demand Driver

Aging global population drives growth in healthcare, medical device and pharmaceutical customer industries that buy STERIS products.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“Much of the growth in these industries is driven by the aging of the population throughout the world”
radioisotope cobalt-60
Supplier Dependency

Cobalt-60 is necessary to AST sterilization operations with few suppliers; company mitigates risk by expanding accelerator-based irradiation capacity.

Relevance 82·Dependency 78·Confidence 93
Source evidence
“we continue to expand our irradiation processing capacity with accelerator-based technologies, in order to help mitigate the potential cobalt-60 supply risk.”
Healthcare procedure volumes
Demand Driver

Increased demand for medical procedures including preventive screenings such as endoscopies and colonoscopies drives demand for STERIS products and services.

Relevance 82·Dependency 65·Confidence 90
Source evidence
“there is increased demand for medical procedures, including preventive screenings such as endoscopies and colonoscopies”
Tariffs
Cost Driver

Tariffs and trade policy changes raise production costs and were a disclosed unfavorable impact on fiscal 2026 gross profit.

Relevance 80·Dependency 60·Confidence 90
Source evidence
“Tariffs, trade restrictions and other changes to international trade policies may result in increased production costs and product pricing, supply chain disruptions, limited access to end markets, lower profitability”
Government-funded healthcare customers
Customer Exposure

Some customers are governmental entities relying on government healthcare funding; funding restrictions could delay or reduce payments and demand, especially for capital products.

Relevance 75·Dependency 60·Confidence 90
Source evidence
“Some of our Customers are governmental entities or other entities that rely on government healthcare systems or government funding.”
Sterigenics
Competitive Exposure

AST segment competes with Sterigenics and other smaller contract sterilization companies in a highly regulated industry.

Relevance 72·Dependency 55·Confidence 92
Source evidence
“AST operates in a highly regulated industry and competes with Sterigenics, other smaller contract sterilization companies”
Cobalt-60
Cost Driver

Cobalt-60 is explicitly named as a component of the capital expenditure program, indicating ongoing investment dependency for the AST segment sterilization business.

Relevance 70·Dependency 55·Confidence 88
Source evidence
“This program includes, among other things, investments in new and existing facilities, business expansion projects, cobalt-60, information technology enhancements, and research and development advances.”
Inflation
Cost Driver

Inflationary pressure on raw materials and energy was a disclosed unfavorable impact on fiscal 2026 gross profit and operating income.

Relevance 70·Dependency 55·Confidence 90
Source evidence
“Favorable impacts from pricing, operational improvements and lower restructuring costs, and productivity were partially offset by unfavorable impacts from tariffs and inflation.”
Tariffs
Cost Driver

Tariffs and trade barriers, particularly as a result of STERIS's corporate structure (Irish domicile), are a disclosed risk to costs and tax liabilities.

Relevance 70·Dependency 45·Confidence 85
Source evidence
“the impact of tariffs and/or other trade barriers as a result of STERIS's corporate structure”
Government healthcare funding
Demand Driver

Government-managed healthcare systems control reimbursement in many countries; budgetary constraints can significantly impact hospital and pharma customers' ability to purchase STERIS products.

Relevance 65·Dependency 55·Confidence 88
Source evidence
“Public budgetary constraints or uncertainties, which may be exacerbated by public health crises, may significantly impact the ability of hospitals, pharmaceutical manufacturers, and other Customers supported by such systems to purchase our products.”
Regulation
Legal Exposure

Regulatory actions and litigation outcomes (including EO litigation) could delay product introductions or impact production, supply and marketing.

Relevance 65·Dependency 40·Confidence 85
Source evidence
“regulatory actions, or the outcome of any pending or threatened litigation, including the EO litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services”
US Dollar
Currency Exposure

Favorable foreign currency movements contributed to fiscal 2026 revenue growth, indicating material non-USD exposure.

Relevance 60·Dependency 50·Confidence 85
Source evidence
“These increases reflect higher volume and pricing, as well as favorable impacts from foreign currency movements.”
Regulation
Demand Driver

Changes in healthcare policy and third-party payor reimbursement levels are a disclosed driver of demand/results.

Relevance 60·Dependency 40·Confidence 80
Source evidence
“changes in healthcare policy or government or other third-party payor reimbursement levels”
Euro
Currency Exposure

STERIS carries €99.0M-equivalent of euro-denominated private placement senior notes (€60.0M at 1.86% due 2027, €20.0M at 2.04% due 2029, €19.0M at 2.30% due 2032), creating euro currency exposure on debt valuation and repayments; revolver outstanding is also based on currency exchange rates.

Relevance 55·Dependency 40·Confidence 90
Source evidence
“€60,000 Senior notes at 1.86% 2017 Private Placement February 202768.9”
Inflation
Cost Driver

Inflation-driven operating cost increases and pricing pressure could erode profit margins.

Relevance 55·Dependency 35·Confidence 80
Source evidence
“operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption ... being greater than expected and leading to erosion of profit margins”
British Pound
Currency Exposure

Pound-denominated private placement notes (£45.0M at 3.04% due 2029 and £30.0M at 3.17% due 2032) create GBP exposure in the debt portfolio.

Relevance 50·Dependency 38·Confidence 90
Source evidence
“£45,000 Senior notes at 3.04%2017 Private Placement February 202959.5 €20,000 Senior notes at 2.04% 2017 Private Placement February 202923.0 £30,000 Senior notes at 3.17% 2017 Private Placement February 203239.7”
Full company information
Latest profile, trading, valuation, and identifier data stored for STE.
Share price
$247.91
Market cap
$24.17B
Exchange
NYSE
Currency
USD
CEO
Daniel A. Carestio
Employees
17,937
IPO date
01/06/1992
Beta
0.865
Last dividend
$0.00
Day range
$234.91 – $249.32
52-week range
$195.14 – $269.44
1-day performance
7.16%
1-year performance
27.04%
Current drawdown (1Y)
-7.99%
CIK
0001757898
CUSIP
N/A
ISIN
IE00BFY8C754
Created
07/12/2025, 14:24:34
Last update
05/11/2026, 09:23:45

Track STERIS plc with an AI analyst

See which prediction-market events move STE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.